Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Bowen Gu joins panel at RI Asia Japan 2018

Bowen Gu, Investor Engagement Researcher at the Access to Medicine Foundation, will speak at the RI Asia Japan 2018 in Tokyo on Wednesday, 11 April, 2018. The goal of the meeting is to bring together global experts to discuss best examples and issues related to sustainable investing and sustainable business practices.

Date

11 April 2018

Bowen will join a panel exploring whether there is an investment case for the 17 Sustainable Development Goals (SDGs) developed by the United Nations and its member states. She will speak on the Foundation’s work on the Access to Medicine Index and analyses on material ESG issues, such as governance & compliance, pricing, patents and licensing, R&D and supply chain management. She will also describe how it aims to incentivise pharmaceutical companies to improve access to medicine in low- and middle-income countries and diffuses best practices within companies, governments and investors.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved